REGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Jane Street Group LLC

Jane Street Group LLC lifted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 325.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 164,911 shares of the biotechnology company's stock after buying an additional 126,135 shares during the quarter. Jane Street Group LLC owned approximately 0.33% of REGENXBIO worth $1,275,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. PDT Partners LLC acquired a new position in REGENXBIO in the fourth quarter valued at approximately $487,000. Voya Investment Management LLC boosted its holdings in REGENXBIO by 7.5% in the fourth quarter. Voya Investment Management LLC now owns 43,502 shares of the biotechnology company's stock valued at $336,000 after purchasing an additional 3,024 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in REGENXBIO in the fourth quarter valued at approximately $3,865,000. Price T Rowe Associates Inc. MD boosted its holdings in REGENXBIO by 9.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock valued at $185,000 after purchasing an additional 1,982 shares in the last quarter. Finally, Quantessence Capital LLC acquired a new position in REGENXBIO in the fourth quarter valued at approximately $270,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director now owns 475,103 shares in the company, valued at $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 12.79% of the company's stock.

REGENXBIO Stock Performance

NASDAQ RGNX traded down $0.15 on Friday, reaching $9.71. The stock had a trading volume of 645,180 shares, compared to its average volume of 880,673. REGENXBIO Inc. has a 12-month low of $5.04 and a 12-month high of $15.39. The business's 50-day moving average price is $7.82 and its 200 day moving average price is $8.02. The stock has a market cap of $487.05 million, a P/E ratio of -1.93 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $89.01 million during the quarter, compared to analysts' expectations of $105.35 million. On average, sell-side analysts predict that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGNX. The Goldman Sachs Group lowered their price target on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Raymond James began coverage on REGENXBIO in a report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target for the company. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. Morgan Stanley boosted their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a research note on Friday, March 14th. Finally, Chardan Capital reiterated a "buy" rating and issued a $52.00 price objective on shares of REGENXBIO in a research note on Thursday, March 20th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.